Sleep Quality & Psoriatic Arthritis
For people living with psoriatic arthritis (PsA), the comfort of a good night's sleep may feel out of reach for many.
Read more →What's hot
View all perspectives
What's Hot
Ultrasound in PsA
Dr. Arthur Kavanaugh discusses abstract 2206 presented at ACR22 in Philadelphia. Abstract 2206: Understanding Inter-rater Variability in Scoring of Entheseal Lesions: Results from the Diagnostic Ultrasound Enthesitis Tool (DUET) Study
Watch video →
Tapering TNFi in nonradiographic AxSpA
Dr. Peter Nash at ACR22 Convergence in Philadelphia, PA.
Watch video →
Sunday (Day 2): ACR 22 Daily Recap
ACR 2022 Daily Recap for Sunday, November 13th. Panelists: Drs. Robert Chao, Antoni Chan, Bella Mehta, Janet Pope, Yuz Yusof, Cassy Sims, Akhil Sood, Sheila Reyes and Jack Cush.
Watch video →
Spondyloarthritis: Novel Therapies, Diagnostic Dilemmas and Depression
Dr. Lianne Gensler discusses the following abstracts presented at ACR22 Convergence. Abstracts 1597, 1598, 1599 (treatment) and 1613, 1609 and 1614 (diagnosis and outcomes)
Watch video →
Deucravacitinib in PsA
Dr. Arthur Kavanaugh discusses abstract 1598 at ACR22 Convergence in Philadelphia. Abstract 1598: Safety and Efficacy of Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor, in Patients with Psoriatic Arthritis: 52-Week Results from a Randomized Phase 2 Trial
Watch video →
Sarilumab in Polymyalgia Rheumatica: Results from SAPHYR Trial
Dr. Michael Putman interviews Dr. Robert Speira about abstract 1676 presented at the ACR22 Convergence meeting in Philadelphia, PA. Abstract 1676: Sarilumab in Patients with Relapsing Polymyalgia Rheumatica: A Phase 3, Multicenter, Randomized, Double Blind, Placebo Controlled Trial (SAPHYR)
Watch video →
PET CT Imaging to Define Risk of Progression from PSO to PsA
Dr. Peter Nash discusses Abstract 1018 at ACR22 Convergence.
Watch video →
ACR22 Daily Recap: Saturday Recap
Panelists: Drs. Jack Cush, Michael Putman, Eric Dein, Patricia Harkins and Rachel Tate.
Watch video →
Dr. Antoni Chan synovialjoints
3 years 1 month ago
Keynote lecture from Abraham Varghese at #ACR22 @RheumNow Opening Session Physicians and Patients
◦ Physical examination is meaningful and cannot be replaced by technology
◦ Don’t treat the EHR, treat the patient
◦ Acknowledge how much goes into patient care by our nurses https://t.co/piV0O8O7Hw
David Liew drdavidliew
3 years 1 month ago
@MayoClinic data for bari in relapsing GCA caused waves at #ACR21
Spanish data looking at real-world practice: slightly longer, slower GCA, but equally encouraging outcomes
waiting for SELECT-GCA with interest! @EBRheum
ABST0464 #ACR22 @RheumNow https://t.co/pVRPXAohhc https://t.co/FgNNfPSWk3
Eric Dein ericdeinmd
3 years 1 month ago
Ab0349 #ACR22 BEL vs AZA ifn risks in non-renal SLE
BEL: lower risk of severe ifn (HR 0.81) and hospitalization for ifn (HR 0.73) through 5 yrs
Challenge to interpret data as 56% of patients were on glucocorticoids and other anti-rheumatic meds
@RheumNow https://t.co/a0tNFn5Wqr
Patricia Harkins DrTrishHarkins
3 years 1 month ago
⬆️ correlation between BASDAI + ASQoL in 🙋♂️ vs 🙋♀️
What does this mean?
❓low disease activity in 🙋♀️ resulting in more marked ⬇️ in QoL❓
OR
❓Is there a need for gender stratified tools of disease activity❓
Abst#0406
#ACR22 @RheumNow @Sineadm15
sheila RHEUMarampa
3 years 1 month ago
A #myositis discussion will not be complete without a slide on myositis antibodies - @JuliePaikMD
Great review slide for trainees!
#ACR22 @Rheumnow #RheumTwitter @rheumarhyme @PhRheumaJr @doktora_ging https://t.co/e6cB344vH8
Dr. Rachel Tate uptoTate
3 years 1 month ago
MIRROR results showed 12-month safety/efficacy support MTX co-therapy w/ pegloticase. No IRs after 6mo of tx and increased resolution of tophi at wk 52. I use MTX in my gout pts on Pegloticase. Are you #rheumtwitter? Abs 0001 #ACR22 @RheumNow https://t.co/FLwOmAYrS4
Recently the FDA approved deucravacitinib, a highly selective TYK2 inhibitor for psoriasis. Trials are positive in psoriatic arthritis and a phase II study in SLE. What about the effects? Presentations from the ACR22 meeting may provide answers.
sheila RHEUMarampa
3 years 1 month ago
🔸DM pts who are anti-TIF-1 Ab+ have higher risk of malignancy
🔸Ovarian cancer - most common
Really important to do cancer screening in #dermatomyositis
#ACR22 @RheumNow https://t.co/jErqcR0Gyr
TheDaoIndex KDAO2011
3 years 1 month ago
Study of IV tocilizumab for GCA that led to FDA approval of intravenous TCZ this year (2/2022) -one of Dr. C Langford's pick for #YearinReview
@rheumnow #ACR22 https://t.co/luxDDluddM
Janet Pope Janetbirdope
3 years 1 month ago
Is it the medication or behaviour that increases mortality? #SLICC grp showed in #SLE severe non-adherence to #HCQ in Yr 1 of #lupus = 3 poor outcomes -more 1 flares, 2 damage, 3 5yr-death. Surrogate of other poor health behaviours and/or HCQ? abst#0343 #ACR22 #ACRBest @RheumNow https://t.co/tTRdyti0sf
Aurelie Najm AurelieRheumo
3 years 1 month ago
OPAL dataset 🇦🇺: 55000+ RA pts, 1/10 first line JAKi. Persistence > if 1st line,< x2 if 3rd line.
1/2 switch JAKi->TNFi
1/3 switch JAKi ->JAKi
Why high proportion of JAKi cycling, when AE reason for switch low?
https://t.co/APdWW7fzJE
Abst #0274 #ACR22 @Rheumnow @ClaireDeakin10 https://t.co/3xM3lQO1wI
Eric Dein ericdeinmd
3 years 1 month ago
Ab#0348 #ACR22: Meta-analysis of Belimumab for CLE w or w/o SLE
13 studies included: 70% with low risk of bias
BEL improved clinical response at W52 vs non-users OR 1.44
Decrease risk of severe cutaneous flare OR 0.51
Most studies against placebo group
@RheumNow https://t.co/2bSwNKRHZZ
David Liew drdavidliew
3 years 1 month ago
TCZ in GCA: what does it mean for diabetes?
post-hoc GiACTA:
HbA1c obvs better with TCZ (PNL dosing)
but then: even after adjusting for PNL dose, apparent benefit
Is there protective effect?
Interesting observation worth investigating
ABST0461 @MGHrheumatology #ACR22 @RheumNow https://t.co/CF1as5y7Yy
Md Yuzaiful Md Yusof Yuz6Yusof
3 years 1 month ago
#ACR22 Year in Review. Dr Varga highlighted work by @Kahlenberglab. Non-lesional skin in patients with #lupus is not normal and is IFN-riched. Also implication for future therapy development to target organ/tissues vs circulation @RheumNow https://t.co/rSnLYrZoMO
Janet Pope Janetbirdope
3 years 1 month ago
#ACR22 Yr in Review. John Varga says novel vaccination immune therapy may reverse #fibrosis - at least in mice. Hope for #scleroderma & other fibrotic diseases. Data need to be transferred into human experiments @RheumNow https://t.co/ybFRXheQq3
Poster Hall